

**TOXICOLOGICAL PROFILE FOR  
CADMIUM**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
Agency for Toxic Substances and Disease Registry**

July 1999

**DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

## UPDATE STATEMENT

A Toxicological Profile for cadmium was released in September 1997. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333



## FOREWORD

This toxicological profile is prepared in accordance with guidelines\* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the hazardous substance described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a hazardous substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.


The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health are identified by ATSDR and EPA.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a hazardous substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

  
Jeffrey P. Koplan, M.D., M.P.H.  
Administrator  
Agency for Toxic Substances and  
Disease Registry

**\*Legislative Background**

The toxicological profiles are developed in response to the Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) which amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed ATSDR to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. The availability of the revised priority list of 275 hazardous substances was announced in the *Federal Register* on November 17, 1997 (62 FR 61332). For prior versions of the list of substances, see *Federal Register* notices dated April 29, 1996 (61 FR 18744); April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); October 17, 1991 (56 FR 52166); October 28, 1992 (57 FR 48801); and February 28, 1994 (59 FR 9486). Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list.

## QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions.

---

### *Primary Chapters/Sections of Interest*

**Chapter 1: Public Health Statement:** The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

**Chapter 2: Health Effects:** Specific health effects of a given hazardous compound are reported by *route of exposure*, by *type of health effect* (death, systemic, immunologic, reproductive), and by *length of exposure* (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section.

**NOTE:** Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

**Pediatrics:** Four new sections have been added to each Toxicological Profile to address child health issues:

- Section 1.6**    **How Can (Chemical X) Affect Children?**
- Section 1.7**    **How Can Families Reduce the Risk of Exposure to (Chemical X)?**
- Section 2.6**    **Children's Susceptibility**
- Section 5.6**    **Exposures of Children**

### **Other Sections of Interest:**

- Section 2.7**    **Biomarkers of Exposure and Effect**
  - Section 2.10**   **Methods for Reducing Toxic Effects**
- 

### **ATSDR Information Center**

**Phone:** 1-888-42-ATSDR  
or 404-639-6357

**E-mail:** [atsdric@cdc.gov](mailto:atsdric@cdc.gov)

**Fax:** 404-639-6359

**Internet:** <http://www.atsdr.cdc.gov>

The following additional material can be ordered through the ATSDR Information Center:

*Case Studies in Environmental Medicine: Taking an Exposure History*—The importance of taking an exposure history and how to conduct one are described, and an example of a thorough exposure history is provided. Other case studies of interest include *Reproductive and Developmental Hazards*; *Skin Lesions and Environmental Exposures*; *Cholinesterase-Inhibiting Pesticide Toxicity*; and numerous chemical-specific case studies.

*Managing Hazardous Materials Incidents* is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

*Fact Sheets (ToxFAQs)* provide answers to frequently asked questions about toxic substances.

---

### ***Other Agencies and Organizations***

*The National Center for Environmental Health (NCEH)* focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. *Contact:* NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

*The National Institute for Occupational Safety and Health (NIOSH)* conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. *Contact:* NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

*The National Institute of Environmental Health Sciences (NIEHS)* is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. *Contact:* NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

---

### ***Referrals***

*The Association of Occupational and Environmental Clinics (AOEC)* has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. *Contact:* AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: [aoec@dgs.dgsys.com](mailto:aoec@dgs.dgsys.com) • AOEC Clinic Director: <http://occ-env-med.mc.duke.edu/oem/aoec.htm>.

*The American College of Occupational and Environmental Medicine (ACOEM)* is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. *Contact:* ACOEM, 55 West Seegers Road, Arlington Heights, IL 60005 • Phone: 847-228-6850 • FAX: 847-228-1856.



## CONTRIBUTORS

### CHEMICAL MANAGER(S)/AUTHORS(S):

Jessilyn Taylor, M.S.  
ATSDR, Division of Toxicology, Atlanta, GA

Rob DeWoskin, Ph.D.  
Research Triangle Institute, Research Triangle Park, NC

Fanny K. Ennever, Ph.D.  
Life Systems Inc., Cleveland, OH

### THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Research Implementation Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.



## PEER REVIEW

A peer review panel was assembled for cadmium. The panel consisted of the following members:

1. Dr. Joseph P. Gould, Research Scientist, School of Civil & Environmental Engineering, Georgia Institute of Technology, Atlanta, GA;
2. Curtis Klaassen, Professor, Department of Pharmacology and Toxicology, University of Kansas, Kansas City, KS; and
3. R. Craig Schnell, Dean, Graduate Studies and Research, Fargo, ND.

These experts collectively have knowledge of cadmium's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.



## CONTENTS

FOREWORD .....	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS .....	vii
CONTRIBUTORS .....	ix
PEER REVIEW .....	xi
LIST OF FIGURES .....	xvii
LIST OF TABLES .....	xix
<b>1. PUBLIC HEALTH STATEMENT .....</b>	<b>1</b>
1.1 WHAT IS CADMIUM? .....	1
1.2 WHAT HAPPENS TO CADMIUM WHEN IT ENTERS THE ENVIRONMENT? .....	2
1.3 HOW MIGHT I BE EXPOSED TO CADMIUM? .....	3
1.4 HOW CAN CADMIUM ENTER AND LEAVE MY BODY? .....	4
1.5 HOW CAN CADMIUM AFFECT MY HEALTH? .....	5
1.6 HOW CAN CADMIUM AFFECT CHILDREN? .....	7
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO CADMIUM? .....	8
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO CADMIUM? .....	11
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	12
1.10 WHERE CAN I GET MORE INFORMATION? .....	13
<b>2. HEALTH EFFECTS .....</b>	<b>15</b>
2.1 INTRODUCTION .....	15
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	15
2.2.1 Inhalation Exposure .....	17
2.2.1.1 Death .....	18
2.2.1.2 Systemic Effects .....	21
2.2.1.3 Immunological and Lymphoreticular Effects .....	56
2.2.1.4 Neurological Effects .....	57
2.2.1.5 Reproductive Effects .....	59
2.2.1.6 Developmental Effects .....	61
2.2.1.7 Genotoxic Effects .....	62
2.2.1.8 Cancer .....	62
2.2.2 Oral Exposure .....	67
2.2.2.1 Death .....	68
2.2.2.2 Systemic Effects .....	102
2.2.2.3 Immunological and Lymphoreticular Effects .....	113
2.2.2.4 Neurological Effects .....	113
2.2.2.5 Reproductive Effects .....	114
2.2.2.6 Developmental Effects .....	117

2.2.2.7	Genotoxic Effects	120
2.2.2.8	Cancer	120
2.2.3	Dermal Exposure	123
2.2.3.1	Death	123
2.2.3.2	Systemic Effects	124
2.2.3.3	Immunological and Lymphoreticular Effects	124
2.2.3.4	Neurological Effects	126
2.2.3.5	Reproductive Effects	126
2.2.3.6	Developmental Effects	126
2.2.3.7	Genotoxic Effects	126
2.2.3.8	Cancer	126
2.3	TOXICOKINETICS	126
2.3.1	Absorption	128
2.3.1.1	Inhalation Exposure	128
2.3.1.2	Oral Exposure	129
2.3.1.3	Dermal Exposure	132
2.3.2	Distribution	134
2.3.2.1	Inhalation Exposure	134
2.3.2.2	Oral Exposure	134
2.3.2.3	Dermal Exposure	137
2.3.3	Metabolism	137
2.3.4	Elimination and Excretion	140
2.3.4.1	Inhalation Exposure	141
2.3.4.2	Oral Exposure	141
2.3.4.3	Dermal Exposure	142
2.3.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	142
2.3.5.1	Summary of Cadmium PBPK Models	144
2.3.5.2	Cadmium PBPK Model Comparison	144
2.3.5.3	Discussion of Cadmium Models	144
2.4	MECHANISMS OF ACTION	156
2.4.1	Pharmacokinetic Mechanisms	156
2.4.2	Mechanisms of Toxicity	161
2.4.3	Animal-to-Human Extrapolations	164
2.5	RELEVANCE TO PUBLIC HEALTH	165
2.6	CHILDREN'S SUSCEPTIBILITY	188
2.7	BIOMARKERS OF EXPOSURE AND EFFECT	197
2.7.1	Biomarkers Used to Identify or Quantify Exposure to Cadmium	198
2.7.2	Biomarkers Used to Characterize Effects Caused by Cadmium	201
2.8	INTERACTIONS WITH OTHER SUBSTANCES	204
2.9	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	206
2.10	METHODS FOR REDUCING TOXIC EFFECTS	207
2.10.1	Reducing Peak Absorption Following Exposure	208
2.10.2	Reducing Body Burden	209
2.10.3	Interfering with the Mechanism of Action for Toxic Effects	211
2.11	ADEQUACY OF THE DATABASE	213
2.11.1	Existing Information on Health Effects of Cadmium	213
2.11.2	Identification of Data Needs	215
2.11.3	Ongoing Studies	222

3. CHEMICAL AND PHYSICAL INFORMATION .....	229
3.1 CHEMICAL IDENTITY .....	229
3.2 PHYSICAL AND CHEMICAL PROPERTIES .....	229
4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL .....	233
4.1 PRODUCTION .....	233
4.2 IMPORT/EXPORT .....	238
4.3 USE .....	238
4.4 DISPOSAL .....	239
5. POTENTIAL FOR HUMAN EXPOSURE .....	241
5.1 OVERVIEW .....	241
5.2 RELEASES TO THE ENVIRONMENT .....	242
5.2.1 Air .....	247
5.2.2 Water .....	248
5.2.3 Soil .....	249
5.3 ENVIRONMENTAL FATE .....	250
5.3.1 Transport and Partitioning .....	250
5.3.2 Transformation and Degradation .....	255
5.3.2.1 Air .....	255
5.3.2.2 Water .....	255
5.3.2.3 Sediment and Soil .....	255
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .....	256
5.4.1 Air .....	256
5.4.2 Water .....	257
5.4.3 Sediment and Soil .....	258
5.4.4 Other Environmental Media .....	259
5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE .....	263
5.6 EXPOSURES OF CHILDREN .....	267
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	270
5.8 ADEQUACY OF THE DATABASE .....	271
5.8.1 Identification of Data Needs .....	271
5.8.2 Ongoing Studies .....	275
6. ANALYTICAL METHODS .....	281
6.1 BIOLOGICAL SAMPLES .....	281
6.2 ENVIRONMENTAL SAMPLES .....	283
6.3 ADEQUACY OF THE DATABASE .....	289
6.3.1 Identification of Data Needs .....	289
6.3.2 Ongoing Studies .....	290
7. REGULATIONS AND ADVISORIES .....	291
8. REFERENCES .....	317
9. GLOSSARY .....	391

## APPENDICES

A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS .....	A-1
B.	USER'S GUIDE .....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....	C-1



## LIST OF FIGURES

2-1	Levels of Significant Exposure to Cadmium—Inhalation .....	36
2-2	Levels of Significant Exposure to Cadmium—Oral .....	95
2-3	Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance .....	145
2-4	A Schematic Representation of the Nordberg-Kjellström Model .....	146
2-5	A Schematic Representation of the Shank Model .....	152
2-6	Existing Information on Health Effects of Cadmium .....	214
5-1	Frequency of NPL Sites with Cadmium Contamination .....	243



**LIST OF TABLES**

2-1	Levels of Significant Exposure to Cadmium—Inhalation	22
2-2	Levels of Significant Exposure to Cadmium—Oral	69
2-3	Levels of Significant Exposure to Cadmium—Dermal	125
2-4	Assumed Model Parameters and Some Physiologic Parameters for the Nordberg-Kjellström Model	148
2-5	Estimated Parameters, Rate of Uptake, Rate Constants, and Biological Half-Lives in Selected Mouse Organs after Subcutaneous and Oral Administration of $^{109}\text{CdCl}_2$	155
2-6	Genotoxicity of Cadmium <i>In Vivo</i>	179
2-7	Genotoxicity of Cadmium <i>In Vitro</i>	181
2-8	Ongoing Studies on the Health Effects of Cadmium	223
3-1	Chemical Identity of Cadmium and Compounds	230
3-2	Physical and Chemical Properties of Cadmium and Compounds	231
4-1	Facilities That Manufacture or Process Cadmium	235
5-1	Releases to the Environment from Facilities That Manufacture or Process Cadmium	244
5-2	Cadmium Content in Selected Foods	260
5-3	Ongoing Studies on the Potential for Human Exposure to Cadmium	276
6-1	Analytical Methods for Determining Cadmium in Biological Samples	284
6-2	Analytical Methods for Determining Cadmium in Environmental Samples	287
7-1	Regulations and Guidelines Applicable to Cadmium	293

